1、 Siemens Healthineers posts strong Q2 results;Siemens Healthineers posts strong Q2 results;adjusted basic earnings per share range widened for outlook due to tariffsadjusted basic earnings per share range widened for outlook due to tariffs May 7,2025 Siemens Healthineers AG today announces its resul

2、ts for the second quarter of fiscal year 2025 ended March 31,2025.Q2 Fiscal Year 2025 V ery good equipment book-to-bill ratio of 1.14 Strong comparable revenue growth of 6.8%Imaging comparable revenue growth of 8.7%;very good adjusted EBIT margin of 22.4%Diagnostics comparable revenue growth of 1.0%

3、;adjusted EBIT margin of 6.3%Varian comparable revenue growth of 12.5%;adjusted EBIT margin of 13.2%mainly due to extraordinarily high equipment revenue share Advanced Therapies comparable revenue growth of 3.7%;very good adjusted EBIT margin of 18.5%Overall adjusted EBIT margin of 16.6%,clearly abo

4、ve prior-year quarter Free cash flow of almost 200 million,clearly above prior-year quarter Adjusted basic earnings per share of 0.56,above prior-year quarter Updated Outlook for Fiscal Year 2025 We confirm our expectation of comparable revenue growth of between 5%to 6%compared with fiscal year 2024

5、.Due to the geopolitical developments in particular trade barriers and increased tariffs on a wide range of countries we now assume an expanded range of between 2.20 and 2.50(previously 2.35 to 2.50)for adjusted basic earnings per share.Bernd Montag,CEO of Siemens Healthineers AG:”We continued our s

6、trong start to the fiscal year in the second quarter.While the fundamental growth drivers remain intact,we expect that the significantly increased volatility of the geopolitical environment will weigh on our business this year.That leads us to widen our guidance range for adjusted basic earnings per

7、 share for fiscal 2025,while keeping our revenue growth outlook unchanged.”Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 2 Business Development Q2 Siemens Healthineers Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Revenue 5,909 5,435 8.7%6.8%Adjusted EBIT 982 822 19%Adjusted EBIT mar

8、gin 16.6%15.1%Net income 537 431 25%Adjusted basic earnings per share 0.56 0.55 3%Basic earnings per share 0.47 0.38 24%Free cash flow 197 120 64%1 Year-over-year on a comparable basis,excluding currency translation and portfolio effects as well as effects in line with revaluation of contract liabil

9、ities from IFRS 3 purchase price allocations.2 Adjusted EBIT is defined as income before income taxes,interest income and expenses and other financial income,net,adjusted for expenses for portfolio-related measures,severance charges,other expenses in connection with restructuring measures within the

10、 meaning of IAS 37 and centrally carried pension service and administration expenses(only excluded from adjusted EBIT of the segments).3 Adjusted basic earnings per share are defined as basic earnings per share,adjusted for expenses for portfolio-related measures,severance charges,and other expenses

11、 in connection with restructuring measures within the meaning of IAS 37,net of tax.4 Free cash flow comprises the cash flows from operating activities and additions to intangible assets and property,plant and equipment included in cash flows from investing activities.Revenue rose by 6.8%in the secon

12、d quarter of fiscal year 2025 to around 5.9 billion.The Imaging and Varian segments,in particular,contributed to this strong revenue growth.From a geographical perspective,the Americas region achieved significant comparable revenue growth,the Asia Pacific Japan region very strong growth,and the Chin

13、a region slight growth.The EMEA region showed a slight revenue decline after very strong growth in the prior-year quarter.Equipment order intake in the second quarter markedly exceeded equipment revenue.The equipment book-to-bill ratio was a very good 1.14.Adjusted EBIT rose by 19%to around 982 mill

14、ion in the second quarter from the prior-year period.This resulted in an adjusted EBIT margin of 16.6%,also higher than in the prior-year quarter.In particular,contributions from strong revenue development as well as cost reductions related to the transformation program of the Diagnostics business h

15、ad a positive effect.Net income was 537 million,up 25%from the prior-year period.The tax rate was 27%,above the low 20%rate in the prior-year quarter.Adjusted basic earnings per share rose slightly to 0.56 from 0.55 in the prior-year period.Higher earnings contributions from the operating business w

16、ere impacted by lower net financial income as well as higher tax expenses.Free cash flow reached almost 200 million,clearly above the prior-year quarter.Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 3 Imaging Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Total adjusted revenue 3,281

17、2,956 11.0%8.7%Adjusted EBIT 736 598 23.0%Adjusted EBIT margin 22.4%20.2%1 Total adjusted revenue is defined as total revenue adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.2 Year-over-year on a comparable basis,excluding currency transla

18、tion and portfolio effects.Revenue in the Imaging segment rose 8.7%on a comparable basis to almost 3.3 billion in the second quarter.Molecular Imaging showed sharp growth and Computed Tomography grew very strongly.From a geographical perspective,Imaging in the Americas region showed sharp comparable

19、 growth and,in the Asia Pacific Japan region,revenue rose slightly.Meanwhile,revenue in the China region declined slightly due to continued delays in customer orders,and,in the EMEA region,revenue also declined slightly against very strong growth in the prior-year quarter.The segments very good adju

20、sted EBIT margin of 22.4%was clearly above the prior-year level thanks to very strong revenue development and a positive special item.Diagnostics Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Total adjusted revenue 1,122 1,104 1.7%1.0%Adjusted EBIT 71 45 56.5%Adjusted EBIT margin 6.3%4.1%1 Total ad

21、justed revenue is defined as total revenue adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.2 Year-over-year on a comparable basis,excluding currency translation and portfolio effects.In the Diagnostics segment,revenue in the second quarter

22、 rose by 1.0%on a comparable basis to around 1.1 billion.In the Asia Pacific Japan region,revenue rose strongly on a comparable basis.Revenue also rose strongly in the China region,here in comparison with a strong decline in revenue in the prior-year quarter.Meanwhile,Diagnostics revenue development

23、 in the EMEA region was flat and,in the Americas region,it declined slightly.The segments adjusted EBIT margin of 6.3%was clearly above the prior-year quarter.The margin development was driven in particular by cost reductions related to the transformation program.Quarterly Statement Q2 Fiscal Year 2

24、025|Siemens Healthineers 4 Varian Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Total adjusted revenue 1,041 910 14.5%12.5%Adjusted EBIT 138 149 7.7%Adjusted EBIT margin 13.2%16.4%1 Total adjusted revenue is defined as total revenue adjusted for effects in line with revaluation of contract liabilit

25、ies from IFRS 3 purchase price allocations.2 Year-over-year on a comparable basis,excluding currency translation and portfolio effects.Revenue in the Varian segment rose by 12.5%on a comparable basis in the second quarter to around 1.0 billion against a slight decline in the prior-year quarter.The A

26、sia Pacific Japan region showed sharp growth and the Americas region significant growth.In the China region,revenue rose strongly against a sharp decline in the prior-year quarter.The EMEA region showed moderate growth.The segments adjusted EBIT margin of 13.2%was below the prior-year quarter,mainly

27、 due to an extraordinarily high equipment revenue share as well as negative currency effects.Advanced Therapies Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Total adjusted revenue 553 526 5.1%3.7%Adjusted EBIT 102 85 20.2%Adjusted EBIT margin 18.5%16.2%1 Total adjusted revenue is defined as total

28、revenue adjusted for effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.2 Year-over-year on a comparable basis,excluding currency translation and portfolio effects.Revenue in the Advanced Therapies segment rose by 3.7%on a comparable basis in the second q

29、uarter to 553 million on top of a very strong prior-year quarter.The segment achieved very strong growth in the Asia Pacific Japan region and strong growth in the Americas region.The China region also grew strongly,here against a significant revenue decline in the prior-year quarter.Revenue in the E

30、MEA region declined moderately against sharp growth in the prior-year quarter.The segments adjusted EBIT margin of 18.5%was clearly above the prior-year quarter.Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 5 Reconciliation to consolidated financial statements Adjusted EBIT Q2 Q2(in m

31、illions of)2025 2024 Total Segments 1,047 878 Corporate items,Eliminations,other items 65 56 Adjusted EBIT 982 822 Amortization,depreciation and other effects from IFRS 3 purchase price allocation adjustments 92 95 Transaction,integration,retention and carve-out costs 6 6 Gains and losses from dives

32、tments 0 0 Severance charges 17 29 Expenses for other portfolio-related measures Other restructuring expenses 27 103 Total adjustments 141 233 EBIT 841 589 Financial income,net 111 47 Income before income taxes 730 541 Income tax expenses 194 110 Net income 537 431 Basic earnings per share Q2 Q2(in)

33、2025 2024 Basic earnings per share 0.47 0.38 Amortization,depreciation and other effects from IFRS 3 purchase price allocation adjustments 0.08 0.09 Transaction,integration,retention and carve-out costs 0.01 0.00 Gains and losses from divestments 0.00 0.00 Severance charges 0.02 0.03 Expenses for ot

34、her portfolio-related measures Other restructuring expenses 0.02 0.09 Financial income due to portfolio related measures Tax effects on adjustments 0.03 0.04 Adjusted basic earnings per share 0.56 0.55 1 Calculated based on the income tax rate of the respective reporting period.Severance charges fel

35、l by 12 million to 17 million and other restructuring expenses fell by 76 million to 27 million.This was mainly due to lower expenses in connection with the transformation of the Diagnostics business.Financial income,net fell by 63 million to-111 million.A change in the fair market valuation of an i

36、nvestment had a negative effect,while a change in the prior-year period in the fair market valuation of another investment had a positive effect.Net income rose by 25%over the prior-year period to 537 million.The tax rate was 27%,above the low rate of 20%in the prior-year quarter,which was impacted

37、by special items.Adjusted basic earnings per share of 0.56 were slightly above the prior-year level of 0.55.Increased earnings contributions from operating business more than compensated for a lower net financial income and the tax rate,which was higher than in the prior-year quarter.Adjustments dec

38、reased from the prior-year period,in particular due to lower other restructuring expenses in connection with the transformation of the Diagnostics business.Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 6 Outlook The geopolitical developments that occurred in the second quarter of fisc

39、al year 2025 and continue to persist,in particular trade barriers and increased tariffs on a wide range of countries,have a negative impact on our business development in fiscal year 2025.For fiscal year 2025,we nevertheless continue to expect comparable revenue growth of between 5%and 6%over fiscal

40、 year 2024.For adjusted basic earnings per share,we now assume an expanded range of between 2.20 and 2.50(previously 2.35 to 2.50)to account for the increased uncertainty.The outlook is based on several assumptions.This includes the expectation that the current macroeconomic environment,including th

41、e regulations with regards to trade tariffs currently in force and planned for implementation as well as the interest rate level,will remain largely unchanged.Based on our assumptions,the trade barriers and tariffs will have slightly negative impacts on the growth dynamics of individual segments and

42、 will reduce the adjusted EBIT margins of all segments in the second half of the fiscal year.In addition,the outlook is based on assumptions about exchange rate developments,which currently lead to a slightly positive currency effect on the expected adjusted basic earnings per share for fiscal year

43、2025 compared with fiscal year 2024.Furthermore,this outlook excludes potential portfolio measures.The outlook is based on the number of shares outstanding at the end of fiscal year 2024.This outlook also excludes additional charges from legal,tax and regulatory issues and framework conditions.Quart

44、erly Statement Q2 Fiscal Year 2025|Siemens Healthineers 7 Notes and forward-looking statments The conference call for journalists with CEO Dr.Bernd Montag and CFO Dr.Jochen Schmitz on the financial figures of the second quarter will be broadcast live on the Internet starting today at 07:30 a.m.CEST:

45、siemens- Starting today at 08:30 a.m.CEST,the conference call for analysts and investors with Dr.Bernd Montag and Dr.Jochen Schmitz can be followed live at:siemens- Recordings of both conferences will be made available afterwards.Financial publications are available for download at:siemens- Contact

46、for journalists Georgina Prodhan Phone:+44 7808 828799;Email:georgina.prodhansiemens- Ulrich Kuenzel Phone:+49 162 2433492;Email:ulrich.kuenzelsiemens- This document contains statements related to our future business and financial performance and future events or developments involving Siemens Healt

47、hineers that may constitute forward-looking statements.These statements may be identified by words such as“expect”,“forecast”,“anticipate”,“intend”,“plan”,“believe”,“seek”,“estimate”,“will”,“target”or words of similar meaning.We may also make forward-looking statements in other reports,in presentati

48、ons,in material delivered to shareholders and in press releases.In addition,our representatives may from time to time make oral forward-looking statements.Such statements are based on the current expectations,plans and certain assumptions of Siemens Healthineers management,of which many are beyond S

49、iemens Healthineers control.As they relate to future events or developments,these statements are subject to various risks,uncertainties and factors,including,but not limited to those possibly described in the respective disclosures.Should one or more of these or other risks,uncertainties or factors(

50、e.g.events of force majeure,including but not limited to unrest,acts of war,pandemics or acts of God)materialize,plans change or should underlying expectations not occur or assumptions prove incorrect,Siemens Healthineers management actions,actual results,performance or achievements of Siemens Healt

51、hineers may(negatively or positively)vary materially from those described explicitly or implicitly in the forward-looking statement.All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends,nor assumes any obligation,unless required by law,

52、to update or revise these forward-looking statements in light of developments which differ from those anticipated.This document includes supplemental financial measures that are or may be alternative performance measures not precisely defined in the applicable financial reporting framework(non-GAAP-

53、measures).These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers net assets and financial positions or results of operations as presented in accordance with the applicable financial r

54、eporting framework.Other companies that report or describe similarly titled alternative performance measures may calculate them differently and therefore they may not be comparable to those included in this document.Please find further explanations regarding our(supplemental)financial measures in ch

55、apter“A.2 Financial performance system”and in the Notes to consolidated financial statements,Note 29“Segment information”of the Annual Report 2024 of Siemens Healthineers.Additional information is also included in the Half-Year Financial Report 2025.These documents are available under the following

56、internet link www.siemens- to rounding,individual numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.This document is an English language translation of the German do

57、cument.In case of discrepancies,the German language document is the sole authoritative and universally valid version.The information contained in this document is provided as of the date of its publication and is subject to change without notice.In the event that the male form is used in this docume

58、nt,the information nevertheless refers to all persons.Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 8 Siemens Healthineers AG Siemensstr.3 91301 Forchheim,Germany siemens- Investor Relations Telefon:+49(9131)84-3385 Email:ir.teamsiemens- siemens- Press Email:press.teamsiemens- siemens

59、- Siemens Healthineers AG,2025 Financial ResultsFinancial Results Second quarter of fiscal year 2025Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 10 Additional information Revenue by region(location of customer)Q2 Q2%Change(in millions of)2025 2024 Act.Comp.Europe,C.I.S.,Africa,Middle

60、 East(EMEA)1,825 1,810 1%1%therein Germany 281 277 2%1%Americas 2,627 2,253 17%14%therein U.S.2,286 1,905 20%16%Asia Pacific Japan 841 778 8%8%China 615 595 3%2%Siemens Healthineers 5,909 5,435 9%7%1 Year-over-year on a comparable basis,excluding currency translation and portfolio effects as well as

61、 effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.2 Including India.Revenue by region(location of customer)First half First half%-Change(in millions of)2025 2024 Act.Comp.Europe,C.I.S.,Africa,Middle East(EMEA)3,619 3,604 0%1%therein Germany 563 533 6%5%

62、Americas 4,995 4,326 15%14%therein U.S.4,310 3,653 18%15%Asia Pacific Japan 1,544 1,429 8%8%China 1,233 1,252 2%3%Siemens Healthineers 11,391 10,611 7%6%1 Year-over-year on a comparable basis,excluding currency translation and portfolio effects as well as effects in line with revaluation of contract

63、 liabilities from IFRS 3 purchase price allocations.2 Including India.Employees Mar 31,Sept 30,(in thousands)2025 2024 Number of employees 73.3 72.3 Germany 16.3 16.3 Outside Germany 57.0 56.0 Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 11 Consolidated statements of income Q2 Q2 Fir

64、st half First half(in millions of,earnings per share in)2025 2024 2025 2024 Revenue 5,909 5,435 11,391 10,611 Cost of sales 3,586 3,429 6,916 6,640 Gross profit 2,323 2,006 4,475 3,971 Research and development expenses 485 474 966 938 Selling and general administrative expenses 991 899 1,964 1,801 O

65、ther operating income 4 5 8 10 Other operating expenses 8 49 12 58 Income from investments accounted for using the equity method,net 2 1 1 1 Earnings before interest and taxes 841 589 1,539 1,182 Interest income 26 31 56 64 Interest expenses 104 111 212 218 Other financial income,net 32 32 36 55 Inc

66、ome before income taxes 730 541 1,347 1,084 Income tax expenses 194 110 332 221 Net income 537 431 1,015 863 Thereof attributable to:Non-controlling interests 6 5 10 6 Shareholders of Siemens Healthineers AG 530 426 1,004 857 Basic earnings per share 0.47 0.38 0.90 0.77 Diluted earnings per share 0.

67、47 0.38 0.89 0.76 Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 12 Consolidated statements of comprehensive income Q2 Q2 First half First half(in millions of)2025 2024 2025 2024 Net income 537 431 1,015 863 Remeasurements of defined benefit plans 26 69 42 37 Therein:Income tax effects

68、 13 22 20 36 Other comprehensive income that will not be reclassified to profit or loss 26 69 42 37 Currency translation differences 773 327 490 404 Cash flow hedges 16 4 14 5 Therein:Income tax effects 7 3 7 2 Cost/Income from hedging 129 70 82 24 Therein:Income tax effects 54 29 35 10 Other compre

69、hensive income that may be reclassified subsequently to profit or loss 629 254 422 386 Other comprehensive income,net of taxes 603 323 464 423 Comprehensive income 66 753 1,479 440 Thereof attributable to:Non-controlling interests 5 6 12 5 Shareholders of Siemens Healthineers AG 70 748 1,467 435 Qua

70、rterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 13 Consolidated statements of financial position Mar 31,Sept 30,(in millions of)2025 2024 Cash and cash equivalents 2,404 2,683 Trade and other receivables 4,608 4,478 Other current financial assets 444 229 Current receivables from the Siemen

71、s Group 21 38 Contract assets 1,731 1,891 Inventories 4,490 4,179 Current income tax assets 119 260 Other current assets 773 684 Total current assets 14,590 14,443 Goodwill 18,034 17,662 Other intangible assets 7,126 7,062 Property,plant and equipment 4,762 4,476 Investments accounted for using the

72、equity method 30 30 Other non-current financial assets 1,355 1,375 Deferred tax assets 439 476 Other non-current assets 570 530 Total non-current assets 32,315 31,612 Total assets 46,906 46,055 Short-term financial debt and current maturities of long-term financial debt 286 268 Trade payables 2,174

73、2,126 Other current financial liabilities 266 242 Current liabilities to the Siemens Group 4,383 2,510 Contract liabilities 3,824 3,628 Current provisions 385 413 Current income tax liabilities 293 391 Other current liabilities 1,658 1,995 Total current liabilities 13,269 11,573 Long-term financial

74、debt 506 514 Provisions for pensions and similar obligations 531 592 Deferred tax liabilities 1,529 1,510 Non-current provisions 181 176 Other non-current financial liabilities 27 34 Other non-current liabilities 468 469 Non-current liabilities to the Siemens Group 11,680 12,941 Total non-current li

75、abilities 14,922 16,234 Total liabilities 28,191 27,806 Issued capital 1,128 1,128 Capital reserve 15,829 15,872 Retained earnings 2,133 2,154 Other components of equity 101 521 Treasury shares 320 433 Total equity attributable to shareholders of Siemens Healthineers AG 18,668 18,199 Non-controlling

76、 interests 47 49 Total equity 18,714 18,248 Total liabilities and equity 46,906 46,055 Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 14 Consolidated statements of cash flows Q2 Q2(in millions of)2025 2024 Net income 537 431 Adjustments to reconcile net income to cash flows from operat

77、ing activities:Amortization,depreciation and impairments 313 329 Income tax expenses 194 110 Interest income/expenses,net 78 79 Income/loss related to investing activities 23 3 Other non-cash income/expenses,net 30 139 Change in operating net working capital Contract assets 34 37 Inventories 11 63 T

78、rade and other receivables 232 129 Receivables from and payables to the Siemens Group from operating activities 12 4 Trade payables 23 45 Contract liabilities 128 115 Change in other assets and liabilities 265 294 Additions to equipment leased to others in operating leases 67 47 Income taxes paid 32

79、7 326 Dividends received Interest received 16 16 Cash flows from operating activities 393 286 Additions to intangible assets and property,plant and equipment 195 166 Purchase of investments and financial assets for investment purposes 2 Acquisitions of businesses,net of cash acquired 35 Disposal of

80、investments,intangible assets and property,plant and equipment 6 1 Cash flows from investing activities 191 200 Purchase of treasury shares 42 Other transactions with owners 13 9 Repayment of long-term debt(including current maturities of long-term debt)48 44 Change in short-term financial debt and

81、other financing activities 4 12 Interest paid 13 10 Dividends paid to shareholders of Siemens Healthineers AG 1,066 Dividends paid to non-controlling interests 9 12 Interest paid to the Siemens Group 117 36 Other transactions/financing with the Siemens Group Issuance of long-term debt 49 Repayment o

82、f long-term debt(including current maturities of long-term debt)5 Change in short-term financial debt and other financing activities 720 273 Cash flows from financing activities 549 174 Effect of changes in exchange rates on cash and cash equivalents 23 10 Change in cash and cash equivalents 370 249

83、 Cash and cash equivalents at beginning of period 2,774 2,056 Cash and cash equivalents at end of period 2,404 2,305 Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 15 Consolidated statements of cash flows First half First half(in millions of)2025 2024 Net income 1,015 863 Adjustments t

84、o reconcile net income to cash flows from operating activities:Amortization,depreciation and impairments 617 619 Income tax expenses 332 221 Interest income/expenses,net 156 154 Income/loss related to investing activities 20 25 Other non-cash income/expenses,net 91 101 Change in operating net workin

85、g capital Contract assets 172 51 Inventories 246 374 Trade and other receivables 74 152 Receivables from and payables to the Siemens Group from operating activities 9 7 Trade payables 8 151 Contract liabilities 164 140 Change in other assets and liabilities 495 422 Additions to equipment leased to o

86、thers in operating leases 155 95 Income taxes paid 259 512 Dividends received 1 Interest received 33 29 Cash flows from operating activities 1,373 656 Additions to intangible assets and property,plant and equipment 365 298 Purchase of investments and financial assets for investment purposes 2 3 Acqu

87、isitions of businesses,net of cash acquired 204 41 Disposal of investments,intangible assets and property,plant and equipment 8 10 Cash flows from investing activities 563 332 Purchase of treasury shares 42 Other transactions with owners 13 9 Repayment of long-term debt(including current maturities

88、of long-term debt)97 97 Change in short-term financial debt and other financing activities 14 15 Interest paid 27 18 Dividends paid to shareholders of Siemens Healthineers AG 1,066 Dividends paid to non-controlling interests 13 16 Interest paid to the Siemens Group 150 96 Other transactions/financin

89、g with the Siemens Group Issuance of long-term debt 49 Repayment of long-term debt(including current maturities of long-term debt)5 20 Change in short-term financial debt and other financing activities 261 9 Cash flows from financing activities 1,089 231 Effect of changes in exchange rates on cash a

90、nd cash equivalents 35 Change in cash and cash equivalents 279 59 Cash and cash equivalents at beginning of period 2,683 2,247 Cash and cash equivalents at end of period 2,404 2,305 Quarterly Statement Q2 Fiscal Year 2025|Siemens Healthineers 16 Overview of segment figures Adjusted external revenue

91、Intersegment revenue Total adjusted revenue Adjusted EBIT Assets Free cash flow Additions to other intangible assets and property,plant and equipment Amortization,depreciation and impairments Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Mar 31,Sept 30,Q2 Q2 Q2 Q2 Q2 Q2(in millions of)2025 2024 2025 2024 2025 2024 2025 2

92、024 2025 2024 2025 2024 2025 2024 2025 2024 Imaging 3,153 2,847 129 108 3,281 2,956 736 598 9,536 8,962 476 402 114 64 50 43 Diagnostics 1,122 1,103 0 0 1,122 1,104 71 45 6,052 5,742 20 27 113 97 84 109 Varian 1,041 910 0 0 1,041 910 138 149 13,785 13,768 118 74 14 40 12 10 Advanced Therapies 552 52

93、5 1 1 553 526 102 85 1,979 1,884 3 39 12 4 5 4 Total Segments 5,868 5,385 130 110 5,998 5,495 1,047 878 31,352 30,356 618 542 254 205 151 166 Reconciliation to Consolidated Financial Statements 41 50 130 110 89 60 317 337 15,554 15,699 420 422 104 80 162 162 Siemens Healthineers 5,909 5,435 5,909 5,

94、435 730 541 46,906 46,055 197 120 358 285 313 329 1 Siemens Healthineers:IFRS revenue.2 Siemens Healthineers:Income before income taxes.3 On segment level:net capital employed.4 Including additions through business combinations,excluding goodwill.5 Including effects in line with revaluation of contr

95、act liabilities from IFRS 3 purchase price allocations.Adjusted external revenue Intersegment revenue Total adjusted revenue Adjusted EBIT Assets Free cash flow Additions to other intangible assets and property,plant and equipment Amortization,depreciation and impairments First half First half First

96、 half First half First half First half First half First half Mar 31,Sept 30,First half First half First half First half First half First half(in millions of)2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Imaging 6,055 5,536 240 211 6,295 5,748 1,301 1,131 9,536 8,962

97、 1,021 859 319 115 99 85 Diagnostics 2,189 2,162 1 0 2,190 2,162 154 99 6,052 5,742 13 80 239 181 163 184 Varian 2,015 1,820 0 1 2,015 1,821 304 295 13,785 13,768 342 158 54 51 24 20 Advanced Therapies 1,050 999 2 2 1,052 1,001 172 153 1,979 1,884 101 83 24 8 10 8 Total Segments 11,309 10,517 243 21

98、4 11,552 10,732 1,932 1,678 31,352 30,356 1,451 1,021 636 354 296 297 Reconciliation to Consolidated Financial Statements 82 94 243 214 161 121 585 594 15,554 15,699 444 663 151 216 322 322 Siemens Healthineers 11,391 10,611 11,391 10,611 1,347 1,084 46,906 46,055 1,007 358 786 570 617 619 1 Siemens

99、 Healthineers:IFRS revenue.2 Siemens Healthineers:Income before income taxes.3 On segment level:net capital employed.4 Including additions through business combinations,excluding goodwill.5 Including effects in line with revaluation of contract liabilities from IFRS 3 purchase price allocations.Quar

100、terly Statement Q2 Fiscal Year 2025|Siemens Healthineers 17 EBITDA reconciliation Adjusted EBIT Therein adjusted for amortization,depreciation and other effects from IFRS 3 purchase price allocation adjustments Therein adjusted for transaction,integration,retention and carve-out costs Therein adjust

101、ed for gains and losses from divestments Therein adjusted for severance charges Therein adjusted for other portfolio-related measures Therein adjusted for other restructuring expenses Amortization,depreciation&impairments EBITDA Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2(in millions of)20

102、25 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Imaging 736 598 1 3 1 11 12 3 17 50 43 770 611 Diagnostics 71 45 0 12 24 78 84 109 131 64 Varian 138 149 2 3 0 1 0 1 12 10 147 154 Advanced Therapies 102 85 0 0 3 2 5 4 105 87 Total Segments 1,047 878 2 4 3 2 0 0

103、 14 28 27 95 151 166 1,153 916 Reconciliation to consolidated financial statements 65 56 90 92 3 4 3 2 8 162 162 0 1 Siemens Healthineers 982 822 92 95 6 6 0 0 17 29 27 103 313 329 1,154 917 1 Income before income taxes,interest income and expenses,other financial income,net as well as amortization,

104、depreciation&impairments.Adjusted EBIT Therein adjusted for amortization,depreciation and other effects from IFRS 3 purchase price allocation adjustments Therein adjusted for transaction,integration,retention and carve-out costs Therein adjusted for gains and losses from divestments Therein adjusted

105、 for severance charges Therein adjusted for other portfolio-related measures Therein adjusted for other restructuring expenses Amortization,depreciation&impairments EBITDA First half First half First half First half First half First half First half First half First half First half First half First h

106、alf First half First half First half First half First half First half(in millions of)2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Imaging 1,301 1,131 2 4 2 18 20 4 19 99 85 1,374 1,175 Diagnostics 154 99 5 26 36 94 163 184 276 162 Varian 304 295 4 6 0 2 1

107、 1 24 20 323 306 Advanced Therapies 172 153 0 0 5 3 10 8 178 157 Total Segments 1,932 1,678 4 7 4 3 0 0 28 50 40 113 296 297 2,151 1,801 Reconciliation to consolidated financial statements 128 114 180 183 5 8 4 3 12 322 322 5 1 Siemens Healthineers 1,804 1,564 183 191 9 11 0 0 32 54 40 126 617 619 2,156 1,802 1 Income before income taxes,interest income and expenses,other financial income,net as well as amortization,depreciation&impairments.